Coherus Oncology, Inc.
CHRS
$1.58
-$0.01-0.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.81% | -66.28% | -82.30% | -86.05% | -89.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.81% | -66.28% | -82.30% | -86.05% | -89.74% |
| Cost of Revenue | 58.29% | -86.17% | -90.44% | -93.08% | -94.51% |
| Gross Profit | 60.56% | 25.47% | -65.43% | -73.98% | -82.02% |
| SG&A Expenses | -16.52% | -21.35% | -26.98% | -33.76% | -37.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.47% | -32.01% | -41.68% | -49.23% | -51.99% |
| Operating Income | 6.67% | 13.78% | 3.41% | 3.92% | 1.28% |
| Income Before Tax | 15.45% | 26.89% | 23.34% | 15.02% | 9.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.45% | 26.89% | 23.22% | 14.88% | 8.96% |
| Earnings from Discontinued Operations | 43.28% | 35.30% | 71.82% | -61.97% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 489.41% | 34,538.00% | 712.65% | -120.85% | 111.98% |
| EBIT | 6.67% | 13.78% | 3.41% | 3.92% | 1.28% |
| EBITDA | 6.13% | 13.53% | 3.49% | 4.28% | 2.09% |
| EPS Basic | 445.44% | 17,176.92% | 582.47% | -62.18% | 110.42% |
| Normalized Basic EPS | 9.80% | 20.22% | 16.46% | 22.42% | 31.01% |
| EPS Diluted | 445.44% | 10,425.58% | 568.57% | -60.00% | 110.36% |
| Normalized Diluted EPS | 9.80% | 20.22% | 16.46% | 22.42% | 31.01% |
| Average Basic Shares Outstanding | 2.26% | 2.05% | 5.90% | 12.72% | 21.94% |
| Average Diluted Shares Outstanding | 2.26% | 2.05% | 5.90% | 12.72% | 21.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |